Skip to content
Company Analysis

Aclaris Therapeutics, Inc. ACRS

A comprehensive view of key metrics, scores, and financial health for Aclaris Therapeutics, Inc.

Overview of Aclaris Therapeutics, Inc.

ACRS NMS
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics Small Cap
Aclaris Therapeutics, Inc. (ACRS), is a Small Cap company, in the Diagnostics & Research industry, last closed at $4.32, about 0.0% overvalued vs fair value, +193.9% 1Y return, ranked 1008/1122 in sector.
USD 4.32
-1.14%
(Delayed)
• Vol 90d: 66.8%
52-Week Range
Market Cap
$572.62M
Enterprise Value
$482.30M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 70%
Confidence: 80%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.aclaristx.com
HQ Wayne, PA
Employees 61
Fiscal year Dec 31

Next Events

Earnings Aug 6 Estimated

Fair Value Snapshot

Bear Base Bull
$-1
$-1
$-1
Current: $4.32

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$7.8M
-58.2%%
Gross Profit
$542.0K
-83.4%%
Operating Income (GAAP)
$-74.1M
-41%%
EBITDA
$-73.6M
-42.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
6.9%
Poor

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Aclaris Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
26
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
14
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 77% Coverage
Trade-Off Triangle Visualization A ternary plot showing ACRS's balance between Growth (33.2%), Profitability (19.6%), and Safety (47.3%). Growth 33% Safety 47% Profitability 20%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

37th percentile vs peers
37
Key Signals
Revenue CAGR 3Y 40.4% 87p EPS Growth YoY -34.8% 18p Rev Growth YoY -40.1% 7p
Strengths
  • Revenue CAGR 3Y in top 20% of peers (40.4%, 87th percentile)
  • Strong liquidity position vs peers
Risks
  • EPS Growth YoY in bottom 20% of peers (-34.8%)
  • Rev Growth YoY in bottom 20% of peers (-40.1%)

Profitability

22th percentile vs peers
22
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

53th percentile vs peers
53
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Aclaris Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.71
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000